

ForPatients

by Roche

Renal Cell Cancer (RCC) Renal Cell Carcinoma

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

Trial Status
Completed

Trial Runs In
21 Countries

Trial Identifier
NCT02420821 2014-004684-20
WO29637

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT02420821 2014-004684-20 WO29637
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
